Investigational antibiotic, Cefiderocol, receives U.S. FDA Advisory Committee recommendation for approval to treat complicated UTIs

Shionogi & Co., Ltd. recently announced that the U.S. Food and Drug Administration's (FDA) Antimicrobial Drugs Advisory Committee voted to recommend approval of the investigational antibiotic cefiderocol for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, in patients with limited or no alternative treatment options. The Advisory Committee voted 14 to 2 that ["]

The post Investigational antibiotic, Cefiderocol, receives U.S. FDA Advisory Committee recommendation for approval to treat complicated UTIs appeared first on Outbreak News Today.